Zacks Investment Research on MSN

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
Zacks Investment Research on MSN

CRISPR Therapeutics AG (CRSP) Stock Moves -2.51%: What You Should Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $62.56, moving -2.51% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.16%, while the tech-heavy Nasdaq ...

A Look at CRISPR Therapeutics’s Valuation Following New CTX460 Gene Editing Breakthrough Data

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

CRISPR Crisis: Intellia Stock Crashes 40% After Shock Trial Pause

A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...

2 Soaring Cathie Wood Stocks to Buy and Hold

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

H.C. Wainwright Remains a Buy on Crispr Therapeutics AG (CRSP)

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Intellia stock tumbles after pausing gene therapy trials on safety concerns

Intellia Therapeutics (NASDAQ:NTLA) stock tumbled 50% Monday after the company announced it has temporarily paused patient dosing and screening for its Phase 3 clinical trials of nex-z due to a ...